Tropisetron (Navoban) in the prevention of chemotherapy-induced nausea and vomiting--the Nordic experience

Research output: Contribution to journalArticle


An open, noncomparative, Nordic multicenter study was carried out during 1991-1992 to evaluate the 5-HT3 receptor antagonist tropisetron (Navoban) as an antiemetic agent for various types of cancer chemotherapy. A total of 630 patients were recruited from 15 centers in Sweden, Denmark, and Finland. Gynecological cancers (60%), breast cancer (15%), and lung cancer (10%) were the main diagnoses. Prior experience of chemotherapy was documented in 338 patients (54%). In 260 patients (41%), cisplatin was part of the cytostatic regimen. Carboplatin (23%), doxorubicin (27%), and epidoxorubicin (24%) were also frequently included. In all, 23 cytostatic agents were used in various combinations. The mean number of courses studied was 4.6 (range 1-19). Altogether, 394 of 619 evaluable patients (64%) were completely protected from acute nausea and vomiting during the first course of chemotherapy. Delayed nausea and vomiting were completely prevented in 45%-73% (days 2-6) in the complete series. Treatment efficacy remained stable (60%-79%) during ten consecutive courses of chemotherapy. With noncisplatin regimens, complete protection from acute nausea and vomiting was achieved in 72% compared with 52% for cisplatin regimens (P < 0.0001). Patients without prior experience of chemotherapy had higher control rates of acute nausea and vomiting (72%) compared to patients treated before (57%) during the first course, but not later on. There were no differences in delayed nausea and vomiting.(ABSTRACT TRUNCATED AT 250 WORDS)


  • B Sorbe
  • H Andersson
  • M Schmidt
  • M Söderberg
  • T Högberg
  • L Wernstedt
  • E T Janson
  • B Ehrnström
  • M Kjaer
  • H Havsteen
  • M Overgaard
  • Erik Sandberg
  • M Flander
  • M Heikkinen
  • V Nikkanen
External organisations
  • Linköping University Hospital
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology


  • Adult, Aged, Aged, 80 and over, Antiemetics/adverse effects, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Female, Finland, Humans, Indoles/adverse effects, Male, Middle Aged, Nausea/chemically induced, Neoplasms/drug therapy, Scandinavian and Nordic Countries, Sex Factors, Treatment Outcome, Tropisetron, Vomiting/chemically induced
Original languageEnglish
Pages (from-to)393-9
Number of pages7
JournalSupportive Care in Cancer
Issue number6
Publication statusPublished - 1994 Nov
Publication categoryResearch
Externally publishedYes